Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?
How many big biotech acquisitions can you name that have occurred so far in 2017?
Johnson & Johnson (NYSE: JNJ) spent $30 billion to buy Swiss biotech Actelion. That's one. Then there's... well, actually, that's it. J&J's acquisition of Actelion is the only truly big biotech buyout year to date, unless you also want to include Japanese drugmaker Takeda's $5.2 billion deal to buy Ariad in the first quarter.
Why has 2017 been such a horrible year so far for biotech acquisitions? Here's the answer -- and why next year could see a flood of deals.
Source: Fool.com
Pfizer Inc. Aktie
26,33 €
-0,09 %
Die Community bevorzugt klar Pfizer Inc. mit vielen Buy- und nur wenigen Sell-Einschätzungen.
Das Community-Kursziel von 41 € für Pfizer Inc. deutet auf eine deutliche Steigerung um mehr als 50% gegenüber dem aktuellen Kurs von 26.33 € hin.
